BRISTOL-MYERS SQUIBB and Celldex Therapeutics Inc. entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, BMS’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
